

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

The cancellations made herein are made without prejudice and are not to be construed as abandonment of the previously-claimed subject matter, or agreement with any objection or rejection of record.

LISTING OF THE CLAIMS:

1. (Cancelled)

2. (Cancelled)

3-7. (Cancelled)

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11-12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23-26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31-60. (Cancelled)

61. (Cancelled)

62-64. (Cancelled)

65. (Cancelled)

66-67. (Cancelled)

68. (Cancelled)

69. (Cancelled)

70. (Cancelled)

71. (Cancelled)

72. (Cancelled)

73. (Cancelled)

74. (Previously Presented) A method of downregulating the inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by introducing follistatin into said mammal, and wherein the inflammatory response occurs in the context of lung transplantation, severe acute respiratory distress syndrome or asthma.

75. (Previously Presented) A method of therapeutically treating a condition characterized by an aberrant, unwanted or otherwise inappropriate inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by administering follistatin to said mammal, and wherein the inflammatory response occurs in the context of lung transplantation, severe acute respiratory distress syndrome or asthma.

76. (Previously Presented) A method of downregulating the inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by introducing follistatin isoform 288 or follistatin isoform 315 into said mammal, and wherein the inflammatory response occurs in the context of lung transplantation, severe acute respiratory distress syndrome or asthma.

77. (Previously Presented) A method of therapeutically treating a condition characterized by an aberrant, unwanted or otherwise inappropriate inflammatory response in a mammal, said method

comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by administering follistatin isoform 288 or follistatin isoform 315 to said mammal, and wherein the inflammatory response occurs in the context of lung transplantation, severe acute respiratory distress syndrome or asthma.

78. (Previously Presented) A method of downregulating the inflammatory response in a mammal, said method comprising downregulating the functional activity of activin A or activin B wherein the downregulation is achieved by introducing follistatin into said mammal, and wherein the inflammatory response occurs in the context of aberrant, unwanted or otherwise inappropriate acute inflammation of the airways.